Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world
  • Posted by Helen Parfitt
  • November 17, 2020
  • News

Therapy Watch launches a new global Lupus tracker

Therapy Watch launches a new global Lupus tracker

This multi country study will report on patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) across core global markets.

read more »

TW Migraine patient snapshot

TW Migraine patient snapshot

An overview of the migraine patient

Our migraine market snapshot offers an introduction to the real world patient data collected by our Therapy Watch migraine study. The snapshot features key patient statistics and a dashboard example.

read more »

The impact of COVID-19 on chronic disease management and the implications for pharma marketing

The impact of COVID-19 on chronic disease management and the implications for pharma marketing

On February 11, 2020, COVID-19 was officially named by the World Health Organisation (WHO). Since then the novel coronavirus causing it, (a severe acute respiratory syndrome) has left its mark on almost every country in the world.

Therapy Watch, our syndicated PRF tracker, has been investigating the impact of COVID-19 on chronic disease management. In this white paper, we share some of the insights and consider future impact.

read more »

  • Posted by Rachel Howard, Brett Gardiner & Richa Munjal
  • June 8, 2020
  • Articles

Breaking policy and perceptual barriers: Biosimilars

Breaking policy and perceptual barriers: Biosimilars

Our specialist market access and Therapy Watch teams analyse RA prescribing data to identify how market access policies across Europe may have impacted the adoption of biosimilars. Read our latest article for pharmaphorum's Deep Dive.

Biologics are big business in Rheumatoid Arthritis (RA), with the first wave of TNF inhibitors Remicade (infliximab), Enbrel (etanercept) and Humira (adalimumab) all having achieved blockbuster sales since their launches in the early 2000s. In recent years, as patents started to expire, an increasing number of branded and generic pharmaceutical companies have launched biosimilars, offering meaningful discounts relative to the originators – an appealing proposition for strained healthcare systems under pressure to contain costs. Leveraging over two years of syndicated RA Therapy Watch data* from September 2017-December 2019 in France, Germany, UK, Italy, and Spain, we looked into what parallels could be drawn between country trends in biosimilar prescribing and individual market policies designed to promote their use.

read more »

  • Posted by Helen Parfitt
  • April 29, 2020
  • News

Therapy Watch panel retention high during Covid-19

Therapy Watch panel retention high during Covid-19

Our syndicated market tracking team has reported that, despite the COVID-19 pandemic, our panel retention rates remain high across all EU markets and Q1 reports have been delivered to all subscribers.
 

read more »